Our blog

Our 'Spotlight On' series interviews individuals across the medical, pharmaceutical and scientific industries, revealing the driving forces behind their company's success. In this interview, we spoke with Ilka Reineman, Executive Director of Business Development EMEA.

Christine Sands is the Divisional Director of our Pharmaceuticals team, with over 14 years of recruitment under her belt. You may know that she manages a team of six and supports companies across EMEA and the US with medical affairs and commercial positions..

November is National Career Development Month, encouraging professionals to celebrate their own career development and focus on their future career choices. First up, we interviewed Christine Sands – our Divisional Director of Pharmaceuticals.

For International Women’s Day, we spoke to three of our female senior managers to find out what it is like being a woman in recruitment, how male-dominated the field really is and what we can do to support women. Our second interview is with Christine Sands who heads up our global pharma team.

Alvogen was looking to hire a Senior Director/Vice President - Business Development to focus on the US generics market. After one day, we presented a shortlist of 4 candidates to Alvogen and in less than 4 weeks, an offer was accepted by a candidate.

Before Brexit, the UK could hire QPs from any location within the EU, but now we can only hire QPs based in the UK – resulting in a lack of supply and a rise in day-rates and salaries. We spoke to the Vice President of Quality at a global biotechnology organisation about the challenges of hiring QPs within the UK, and how these might be overcome.

In the US, we are beginning to see the start of the predicted ‘turnover tsunami’ and it might not be long until we see something similar across Europe and the UK. But why is this happening and what can employers do to not only retain existing employees but to also attract those individuals looking for a change of career?

An established pharmaceutical company in Europe that develops, manufactures and markets generic medications planned to continue its growth strategy by opening a new subsidiary to target the US generics market. To develop and commercialise a portfolio of generic drugs to market, the company needed a US General Manager.

In 2019, the US biosimilar market was worth $737.2 million and continues to grow with a CAGR of 46.2% forecast for 2020-2027, however many are frustrated at the current rate of adoption in the US. But with increasing healthcare costs and a growing debt from Covid-19, what does the next year hold for biosimilar adoption across the US?